Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
2000 1
2004 1
2005 2
2011 1
2012 1
2015 1
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.
Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT; National Institute on Aging; Alzheimer’s Association. Montine TJ, et al. Acta Neuropathol. 2012 Jan;123(1):1-11. doi: 10.1007/s00401-011-0910-3. Epub 2011 Nov 20. Acta Neuropathol. 2012. PMID: 22101365 Free PMC article.
Major revisions from previous consensus criteria are: (1) recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment, (2) an "ABC" score for AD neuropathologic change that incorporates histopathologic assessments of amyloid bet …
Major revisions from previous consensus criteria are: (1) recognition that AD neuropathologic changes may occur in the apparent absence of c …
CART treatment improves memory and synaptic structure in APP/PS1 mice.
Jin JL, Liou AK, Shi Y, Yin KL, Chen L, Li LL, Zhu XL, Qian L, Yang R, Chen J, Xu Y. Jin JL, et al. Sci Rep. 2015 May 11;5:10224. doi: 10.1038/srep10224. Sci Rep. 2015. PMID: 25959573 Free PMC article.
Major characteristics of Alzheimer's disease (AD) include deposits of beta-amyloid (Abeta) peptide in the brain, loss of synapses, and cognitive dysfunction. ...Compared to age-matched wild type mice, 8-month-old APP/PS1 mice had significantly greater CART …
Major characteristics of Alzheimer's disease (AD) include deposits of beta-amyloid (Abeta) peptide in the brain, loss o …
Cerebral amyloid angiopathy in a 95+ cohort: complement activation and apolipoprotein E (ApoE) genotype.
Tanskanen M, Lindsberg PJ, Tienari PJ, Polvikoski T, Sulkava R, Verkkoniemi A, Rastas S, Paetau A, Kiuru-Enari S. Tanskanen M, et al. Neuropathol Appl Neurobiol. 2005 Dec;31(6):589-99. doi: 10.1111/j.1365-2990.2005.00652.x. Neuropathol Appl Neurobiol. 2005. PMID: 16281907
There is growing evidence that in Alzheimer's disease (AD) amyloid beta-protein (Abeta) triggers a chronic inflammatory reaction in cerebral amyloid plaques, including complement proteins. ...The brains had been studied for AD post-mortem, allowing us …
There is growing evidence that in Alzheimer's disease (AD) amyloid beta-protein (Abeta) triggers a chronic inflammatory …
Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
Rüb U, Stratmann K, Heinsen H, Seidel K, Bouzrou M, Korf HW. Rüb U, et al. J Alzheimers Dis. 2017;57(3):683-696. doi: 10.3233/JAD-161102. J Alzheimers Dis. 2017. PMID: 28269779 Review.
New therapeutic attempts aimed to prevent, reduce, or remove the extracellular depositions of the amyloid-beta protein did not elicit beneficial effects on cognitive deficits or functional decline of AD. In view of the failure of these amyloi …
New therapeutic attempts aimed to prevent, reduce, or remove the extracellular depositions of the amyloid-beta …
The effect of oxidative stress on amyloid precursor protein processing in cells engaged in beta-amyloidosis is related to apolipoprotein E genotype.
Mazur-Kolecka B, Kowal D, Sukontasup T, Dickson D, Frackowiak J. Mazur-Kolecka B, et al. Acta Neuropathol. 2004 Oct;108(4):287-94. doi: 10.1007/s00401-004-0890-7. Epub 2004 Jun 19. Acta Neuropathol. 2004. PMID: 15221339
The reduced antioxidative defense in allele epsilon4 carriers is suggested to contribute to beta-amyloidosis in Alzheimer's disease and Down's syndrome. We studied the effect of oxidative stress on accumulation of amyloid-beta peptide (Abeta) in vascular smoo …
The reduced antioxidative defense in allele epsilon4 carriers is suggested to contribute to beta-amyloidosis in Alzheimer's disease a …
Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.
Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Cataldo AM, et al. Am J Pathol. 2000 Jul;157(1):277-86. doi: 10.1016/s0002-9440(10)64538-5. Am J Pathol. 2000. PMID: 10880397 Free PMC article.
Endocytosis is critical to the function and fate of molecules important to Alzheimer's disease (AD) etiology, including the beta protein precursor (betaPP), amyloid beta (Abeta) peptide, and apolipoprotein E (ApoE). ...To evaluate endocytic activation, …
Endocytosis is critical to the function and fate of molecules important to Alzheimer's disease (AD) etiology, including the beta p …
Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner.
Thal DR, Capetillo-Zarate E, Schultz C, Rüb U, Saido TC, Yamaguchi H, Haass C, Griffin WS, Del Tredici K, Braak H, Ghebremedhin E. Thal DR, et al. Acta Neuropathol. 2005 Nov;110(5):459-71. doi: 10.1007/s00401-005-1053-1. Epub 2005 Sep 30. Acta Neuropathol. 2005. PMID: 16195918
Different types of amyloid beta-protein (Abeta)-containing plaques occur in brains of Alzheimer's disease (AD) patients. ...In 10 additional cases, immunoreactivity against apoE was completely lacking in newly formed plaques, which, at the same time, d …
Different types of amyloid beta-protein (Abeta)-containing plaques occur in brains of Alzheimer's disease (AD) patients …
Inconstant apolipoprotein E (ApoE)-like immunoreactivity in amyloid beta protein deposits: relationship with APOE genotype in aging brain and Alzheimer's disease.
Uchihara T, Duyckaerts C, Lazarini F, Mokhtari K, Seilhean D, Amouyel P, Hauw JJ. Uchihara T, et al. Acta Neuropathol. 1996 Aug;92(2):180-5. doi: 10.1007/s004010050506. Acta Neuropathol. 1996. PMID: 8841664
The aim of this study was to analyze the relationship between apolipoprotein E (ApoE) and amyloid beta-protein (A beta) deposits in 29 brains from a series of elderly women, whose intellectual status had been prospectively assessed by the Blesse …
The aim of this study was to analyze the relationship between apolipoprotein E (ApoE) and amyloid beta-protein (A be …
Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease.
Gearing M, Mori H, Mirra SS. Gearing M, et al. Ann Neurol. 1996 Mar;39(3):395-9. doi: 10.1002/ana.410390320. Ann Neurol. 1996. PMID: 8602762
Apolipoprotein E (ApoE) epsilon4 allele, a risk factor for the development of Alzheimer's disease (AD), is associated with increased amyloid deposition. We examined cerebral cortex in 68 AD cases using antibodies to beta-amyloid (Abeta) peptides of dif …
Apolipoprotein E (ApoE) epsilon4 allele, a risk factor for the development of Alzheimer's disease (AD), is associated with increased amyl …